Earle (27)

25 retarded UP/BP

outpatient females

IMI 150 mg + thyroid hormone,

open label, trial length not

reported

14 of 25 (56%) responders

Ogura et al. (71)

44 UP/BP males and

females

TCA + T₃; open label, trial length

not reported

29 of 44 (66%)responders

Banki (5)

49 UP/BP females

33 T₃; 16 controls

AMI 75-200 mg or AMI 75-200 mg

+ 20-40 mg of T₃, open label, trial

length not reported

T₃: 23 of 33 (70%) responders

Controls: 4 of 16 (25%)

responders

T₃ > control

Tsutsui et al. (111)

11 males

TCA + 5-25 mg of T₃, open label,

trial length not reported

10 of 11 (91%) responders

Goodwin et al. (39)

6 males, 6 females;

3 UP/9 BP

IMI or AMI 150-300 mg + 25 or 50

µg of T₃, 3 wks, double blind

(within-subject-design)

8 of 12 (67%) responders

4 of 12 (33%) remitted

Targum et al. (101)

7 males, 14 females;

all UP

TCA + 25 mg of T₃ or 100 mg of

thyroxine, 3 wks, open label

7 of 21 (33%) responders

Subclinically hypothyroid: 5 of 6

(83%)

Euthyroid patients: 2 of 15

(13%)

Gitlin et al. (37)

9 males, 7 females;

all UP

IMI, mean dose 206 mg, 4wks, ±25

mg of T₃ or placebo, 2 wks, double

blind/crossover

T₃ = PBO. Patients in both groups

improved signigicantly.

Response rates not reported.

Thase et al. (105)

4 males, 16 females;

all UP

IMI, mean dose 240 mg, {ewc MVIMG, MVIMAGE,!greateq.BMP}12 wks +

25 mg T₃, 4 wks; 20 controls

received continued IMI without T₃

T₃: 5 of 20 (25%) responders

Controls: 4 of 20 (20%)

responders

Joffe and Singer (46)

14 males, 24 females;

all UP

Desipramine (n = 35) or IMI (n = 5);

dose 2.5-3.0 mg/kg. T₃ (37.5 mg;

n = 17) vs. T₄ (150 µg; n = 21), 3

wks

T₃: 10 of 17 (59%) responders

T₄: 4 of 21 (19%) responders

T₃  > T₄

Josse et al. (47)

20 males, 31 females;

all UP outpatients

Desipramine (n = 46) or IMI (n = 5);

T₃ (37.5 mg) vs. Li₂CO₃ (900mg)

vs PBO; randomized, double-blind

T₃: 10 of 17 (59%) responders

LI: 9 of 17 (53%) responders

PBO: 3 of 16 (19%) responders

T₃ = Li > PBO